RxDoctor Payments DataLook up a doctor →

Nataliya Uboha, MD

Hematology & Oncology · New Haven, CTNPI 1619146347

Payments from drug & device makers

$13,348,745in general payments, 2019–2025

Across 545 payments — averaging $24,493 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Ipsen Biopharmaceuticals, Inc$4.7M
  • Mirati Therapeutics, Inc.$2.7M
  • Merck$2.4M
  • AstraZeneca$696K
  • Deciphera Pharmaceuticals Inc.$506K
  • Taiho Oncology, Inc.$463K
  • plus $1.8M from 32 others
$14,775in research payments, 2019–2025

Across 3 payments — averaging $4925.14 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$15K
  • Taiho Oncology, Inc.$44

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Ipsen Biopharmaceuticals, Inc56$4,723,705
Mirati Therapeutics, Inc.26$2,712,404
Merck86$2,422,072
AstraZeneca29$695,901
Deciphera Pharmaceuticals Inc.80$505,872
Taiho Oncology, Inc.69$462,879
Seagen Inc.30$285,537
Eli Lilly5$252,516
Astrazeneca UK Limited4$214,952
Sanofi US Services Inc.13$181,852
Pfizer9$166,045
Beone Medicines USA, Inc.7$128,547
EMD Serono, Inc.1$85,443
Novartis3$81,982
Incyte Corporation47$77,714
GSK6$74,504
Chugai Pharmaceutical Co., Ltd.2$68,003
Macrogenics, Inc.3$46,806
Halozyme Inc5$39,671
Lilly USA, LLC16$27,656
EMD Serono Research & Development Institute, Inc.2$25,152
Aadi Bioscience, Inc.1$16,166
Gilead5$16,139
Beigene USA, Inc.7$8,670
Astellas Pharma US Inc4$6,815
E.r. Squibb & Sons, L.L.C.9$4,685
Eisai Inc.3$3,672
Jazz Pharmaceuticals Inc.2$3,486
Helsinn Therapeutics (U.S.), Inc.1$2,813
Array Biopharma Inc2$2,638
Bayer1$1,748
Takeda Pharmaceuticals U.S.A., Inc.1$500
Ipsen Bioscience Inc.1$480
Beigene, Ltd.1$450
Novocure Inc.1$442
Genentech USA, Inc.3$389
Foundation Medicine, Inc.2$365
Tesaro, Inc.2$76

How this compares

$13,348,745 in reported general payments places this provider in the 95th percentile of 163 hematology & oncology providers in Connecticut.

See all hematology & oncology providers in Connecticut →

Medicare billing

Part B allowed, 2024
$48,339
Medicare patients
161
Services billed
736

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in New Haven

See the full list for Connecticut →

Where these figures come from

Is this you, or does something look wrong? →